Following the Company’s Fix, Fund, Propel
approach, Dr. Blue’s promotion highlights deep expertise,
commitment to quality, and focus on advancement of innovative
technology to market.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced the promotion of Michael Sherman Blue, M.D., FACEP to the
position of Chief Medical Officer (CMO), reporting directly to the
Company’s Board of Directors. Dr. Blue’s appointment aligns with
the Company’s stated objectives and its Fix, Fund, Propel approach
to advancing innovative technology to market.
Demonstrated Leadership, Clinical Expertise, Business
Acumen
Michael Blue, M.D., FACEP’s appointment to the role of CMO,
expanding his previous role as Senior Medical Director, continues
Navidea’s work, supported by G2G Ventures as Executive Consultants,
to ensure well-defined organizational roles, clear priorities and
strong leadership to guide the Company forward. In his role, Dr.
Blue’s responsibilities include product strategy and development,
marketing, financial performance, and delivery of shareholder
value. Dr. Blue, reporting to the Board of Directors, will oversee
the delivery of Navidea’s NAV3-32 and NAV3-33 clinical trials, and
the development of expert teams responsible for advancing its
innovative technology to market.
“Dr. Blue’s experience in precision immunodiagnostics,
immunotherapeutics and the biotech industry is important as we
continue pressing the business forward,” said Dr. Jason Myers,
Owner and Founder of G2G Ventures. “Since joining the Company over
a decade ago, Dr. Blue has certainly gained the support and
confidence of his colleagues. His understanding of the business
side of innovation and driving our clinical trials, in concert with
his perspective and experience working with patients, will help
bring Navidea’s technology and assets to the forefront.”
Dr. Blue has served as Senior Medical Director at Navidea since
2011, continuing a decorated career of over 40 years in medicine
which has included roles within emergency center care,
cardiometabolic care, service within committees and community
focused medical advisory positions, leadership roles within
hospitals, and educational roles within multiple universities. His
experience also includes having led healthcare related research for
a regional venture capital firm. Dr. Blue is former Chairman of the
Department of Emergency Medicine at St Ann’s Hospital, former
member of the Board of Directors for the Central Ohio Trauma
System, and is currently Medical Director for Cardinal Health NPHS.
Dr. Blue earned a B.S. in Zoology from Miami University, where he
was also Miami’s Scholar Athlete of the Year, and a Doctor of
Medicine (M.D.) from the Ohio State University School of Medicine.
He holds medical licenses in Ohio, California and Florida, along
with ACLS Certification. Dr. Blue is a member of the American
College of Emergency Physicians and a Fellow of the American Board
of Emergency Medicine, where he also holds a Board Certification in
Emergency Medicine (FACEP).
Dr. Blue has led or contributed to 16 clinical trials related to
Lymphoseek® and concepts related to Navidea’s Manocept platform,
and has published extensively in peer reviewed journals throughout
his career.
“Navidea’s transformative technology holds the potential to
improve lives around the world in many ways,” said Dr. Blue. “I am
honored to step into the role of Chief Medical Officer, and ready
to get to work so we can place our innovative solutions in the
hands of those who need them most.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, visit www.navidea.com.
About G2G Ventures
G2G Ventures is a Colorado-based private equity firm focused on
empowering organizations to reach their full potential through
investment and consulting services. Specializing in creating
long-term partnerships with trusted investors and established
businesses, G2G Ventures draws on strong internal balance sheet
liquidity, augmented by trusted investor capital, to craft bespoke
capital solutions which include private equity investment, venture
capital participation, and mezzanine debt options. Beyond financial
investment, G2G Ventures provides accretive consulting services to
help clarify strategic goals and key performance indicators (KPIs),
evolve financial processes, and enhance operational effectiveness.
To learn more about how G2G Ventures is a growth partner for
enduring business, connect with our team.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230511005965/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. G2G Ventures - Executive Consultant Theodore Gerbick Chief
Marketing Officer tgerbick@g2g.ventures
Navidea Biopharmaceuticals (AMEX:NAVB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Gráfica de Acción Histórica
De May 2023 a May 2024